BMY Stock: Bristol-Myers Squibb Company Stock Price, Analysis & Insights
Get live bmy stock price $45.62, comprehensive Bristol-Myers Squibb Company stock analysis, charts, news, and expert forecast. Real-time bmy stock data and investment insights.
Loading chart...
Company Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Company Information
- CEO
- Christopher S. Boerner
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 34100
Contact Information
- Website
- https://www.bms.com
- Address
- 430 East 29th Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 15.4)
✓ Lower volatility stock (Beta: 0.31) may provide portfolio stability
Business Model & Strategy
Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a mid-cap company, Bristol-Myers Squibb Company benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Christopher S. Boerner, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Bristol-Myers Squibb Company competes in the Drug Manufacturers - General within the broader Healthcare. With 92.9 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Bristol-Myers Squibb Company provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Bristol-Myers Squibb Company should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Bristol-Myers Squibb Company shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Bristol-Myers Squibb Company
- ⚠Investors should consider how Bristol-Myers Squibb Company fits within their overall portfolio allocation
Market Cap
92.87B
P/E Ratio
15.36
Beta
0.31
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 92.87B market capitalization
- Trading Volume: 13.20M shares traded today
- Price Range: 52-week range of $42.52 - $63.33
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 92.87B, the company represents a significant player in its market. The stock is currently trading at $45.62 with a negativedaily change of 0.87%.
The company's 34100 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 15.36, beta of 0.31, and 52-week price range from $42.52 to $63.33when evaluating investment opportunities.
Why Invest in Bristol-Myers Squibb Company?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Christopher S. Boerner
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.